JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement

JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
 
PARSIPPANY, N.J., June 30 /PRNewswire/ -- JHP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectables, vaccines, ophthalmics and otics announced today that it has entered into a multi-year contract supply agreement with an undisclosed ophthalmic company.  Under terms of the agreement, JHP will be responsible for manufacturing and supply of a proprietary ophthalmic product, which is targeted for launch next year.

Stuart Hinchen co-founder and president of JHP stated, "We are very pleased that JHP was chosen for this large-scale multi-year contract.   Our knowledgeable staff, approach to technology transfer and cGMP compliance record with the FDA, EMEA and ANVISA allows us to serve this important customer.  We have a long history of successful partnerships, manufacturing both commercial products and products in development with experience taking products from clinical trial supplies to commercial manufacturing."

About JHP Pharmaceuticals, LLC

JHP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectable products for large and small pharmaceutical and biotech organizations.

JHP's sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and 44,000 sq. ft. warehouse. The production facility utilizes five high-speed filling lines and seven lyophilizers.  The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.

JHP has the capability to manufacture small-scale clinical or large-scale commercial products.  JHP employs more than 330 staff in the USA in its manufacturing, sales & marketing and corporate areas.  For more information, please visit www.jhppharma.com.

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.